Taken together, these results show systemic administration of IL-12 specifically enhances the activation of hepatic T cells, but not splenic T cells, which leads to the further development of IFNγ+ T cells in a RENCA tumor-dependent manner. The gene discussed is IFNG; the disease is neoplasm.